Macrophage Polarization States in the Tumor Microenvironment
Open accessThe DOI matches its Crossref record; 147 of the 148 references it cites were found in a registry or an index.
Abstract
The M1/M2 macrophage paradigm plays a key role in tumor progression. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The tumor microenvironment (TME) can influence macrophage recruitment and polarization, giving way to these pro-tumorigenic outcomes. Investigating TME-induced macrophage polarization is critical for further understanding of TAM-related pro-tumor outcomes and potential development of new therapeutic approaches. This review explores the current understanding of TME-induced macrophage polarization and the role of M2-polarized macrophages in promoting tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that MSCs have the ability to polarize M1 pro-inflammatory macrophages towards an alternative M2 anti-inflammatory phenotype [21,22,23].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, CD4+ T cells impact cancer immunology (30), M1 macrophages suppress tumors, and M2 macrophages aid tumor growth (31).”
From A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer (2025) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, CD4+ T cells impact cancer immunology (30), M1 macrophages suppress tumors, and M2 macrophages aid tumor growth (31).”
From A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer (2025) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 3×
“These CD8+ T and NK cells express high levels of cytokines such as IFN-γ, GM-CSF, and TNF-α as well as chemokines such as CCL4, CCL5, and CCL23 that assist in the further recruitment of immune cells and the signaling of anti-tumorigenic pathways [73,74].”
BackgroundMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 2×
“MDSCs express high levels of both iNOS and arginase-1, which both play a direct role in suppression of T-cell function [95].”
BackgroundOrigin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 1×
“Inflammation can be triggered by conditions such as infection or injury or can be systemic as seen in type 2 diabetes and cardiovascular disease [59].”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 3×
“Current literature supports the theory that most TAMs originate from either tissueresident embryonic macrophages or macrophages derived from circulating monocytes that originate in the bone marrow [87].”
BackgroundMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 3×
“The significance of macrophage heterogeneity has been under review since the early 2000s and has been linked to many malignancies and autoimmune disorders in recent years [66].”
BackgroundProtective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · cited 1×
“The resolution of inflammation is led by the deactivation of these inflammatory mediators, permitting either the apoptosis of pro-inflammatory M1 macrophages or the transition to an anti-inflammatory M2 macrophage [64].”
BackgroundMacrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684 · cited 15×
“Macrophages are found in every human tissue in the body and exhibit anatomical and functional diversity [4].”
BackgroundInfluentialMurray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981 · cited 2×
“Some noncytokine, extrinsic pathways of macrophage polarization do exist, however, including hypoxia as well as the production of lactate within tumors, which drive M2 polarization [36].”
BackgroundFibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Cited by
Items 101–200 of 1,000
Bhatt, M., Sharma, M., & Das, B. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01519-9 · Cited by 68
Gao, X., Zhou, S., Qin, Z., Li, D., Zhu, Y., & Ma, D.-N. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03918-w · Cited by 62
“Among these, tumor-associated macrophages (TAMs), which account for the largest proportion of cells, can inhibit antitumor immune responses by secreting various mediators, further stimulate angiogenesis, and ultimately promote the occurrence and development of cancer cells [18].”
BackgroundChemotherapy-induced metastasis: molecular mechanisms and clinical therapies
Su, J.-X., Li, S.-J., Zhou, X., Zhang, Z., Yu, Y., Liu, S.-L., & Qi, Q. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01093-8 · Cited by 59
“M1 macrophages are thought to be anti-tumorigenic, whereas M2-polarized macrophages elicit several pro-tumorigenic events including angiogenesis, lymphangiogenesis, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis [67].”
BackgroundChen, S., Zeng, J., Li, R., Zhang, Y., Tao, Y., Hou, Y., Lu, Y., Zhang, Y., Wu, J., & Meng, X. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117838 · Cited by 60
Brown, B., Ojha, V., Fricke, I., Al-Sheboul, S. A., Imarogbe, C., Gravier, T., Green, M., Peterson, L., Koutsaroff, I. P., Demir, A. N., et al. (2023) · Vaccines · doi:10.3390/vaccines11020408 · Cited by 58
Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research
Son, B., Lee, W., Kim, H., Shin, H., & Park, H. H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07077-8 · Cited by 60
“Consequently, the anti-in fl ammatory environment induced by these M2 macrophages contributes to therapeutics resistance [263, 279 – 281].”
BackgroundTargeting macrophages in cancer immunotherapy: Frontiers and challenges
Liu, Y., Tan, H., Dai, J., Lin, J., Zhao, K., Hu, H., & Zhong, C. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.043 · Cited by 67
“Macrophages are highly plastic cells that undergo different forms of activation of different signals [17], they have polarized into two subsets under a special microenvironment: classically activated M1 macrophages and alternatively activated M2 macrophages which have 4 subcategories: M2a, M2b, M2c…”
Khouzam, R. A., Janji, B., Thiery, J., Zaarour, R. F., Chamseddine, A. N., Mayr, H., Savagner, P., Kiéda, C., Gad, S., Buart, S., et al. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.008 · Cited by 58
Massaro, F., Corrillon, F., Stamatopoulos, B., Dubois, N., Ruer, A., Meuleman, N., Bron, D., & Lagneaux, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267550 · Cited by 60
“Each status is characterized by speci fi c markers: M1 markers re fl ects the pro-in fl ammatory activity exerted by macrophages while M2 markers amplify signals promoting tissue repair, angiogenesis and cell proliferation (68).”
BackgroundLi, E., Cheung, H. C., & Ma, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-68109-z · Cited by 67
“They can be generally classified into M1 anti-tumor and M2 pro-tumor 15 , but this system does not show the heterogenic role of TAM in detail.”
BackgroundWang, H., Liu, J., Jiang, Y., Wang, Z., Zhang, Z., Peng, J., Wang, Y., & Li, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943389 · Cited by 67
Exploring neutrophil functionality in breast cancer progression: A review
Obeagu, E. I., & Obeagu, G. U. (2024) · Medicine · doi:10.1097/md.0000000000037654 · Cited by 55
“[24] Cytokines and Chemokines are secreted by both immune and tumor cells and play a crucial role in regulating immune responses and shaping the tumor microenvironment.”
BackgroundReprogram to heal: Macrophage phenotypes as living therapeutics
Ghamangiz, S., Jafari, A., Maleki, H., Azimi, H., & Mazloomi, E. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123601 · Cited by 56
Chen, R., Li, Q., Xu, S., Ye, C., Tian, T., Jiang, Q., Shan, J., & Ruan, J. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02435-4 · Cited by 57
The role of macrophages in the tumor microenvironment and tumor metabolism
Sadhukhan, P., & Seiwert, T. Y. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-023-00988-2 · Cited by 53
Zheng, J., Jiang, J., Pu, Y., Xu, T., Sun, J., Zhang, Q., He, L., & Liang, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1248421 · Cited by 55
“In response to local cues, macrophages are usually activated into two different phenotypes: “M1” phenotypes and “M2” phenotypes (Boutilier and Elsawa, 2021).”
BackgroundInfluentialBeyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-γδ T strategies in solid tumor immunotherapy
Hou, Y., Hu, S., Chong, L., Chen, X., Wang, Y., Li, Y., Fu, Z., Feng, C., Gong, Y., Liu, Z., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1675807 · Cited by 61
“Furthermore, the reversibility of macrophage polarization towards the M1 or M2 phenotype plays a pivotal role in cancer therapy, offering potential therapeutic targets and strategies (139).”
Mao, N., Dai, Y., Zhou, H., Lin, F., Zheng, T., Li, Z., Yang, P., Zhao, F., Li, Q., Wang, W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr1576 · Cited by 51
“In addition, CD4 + T cells impact cancer immunology ( 30 ), M1 macrophages suppress tumors, and M2 macrophages aid tumor growth ( 31 ).”
Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
Dang, B.-T. N., Kwon, T. K., Lee, S., Jeong, J., & Yook, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.007 · Cited by 55
Verona, F., Bella, S. D., Schirano, R., Manfredi, C., Angeloro, F., Bozzari, G., Todaro, M., Giannini, G., Stassi, G., & Veschi, V. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529847 · Cited by 56
“Within the TME, TAMs predominantly display a M2 phenotype, which is known for its role in promoting immunosuppression (176).”
Rodríguez, J. P., Casas, J., Balboa, M. A., & Balsinde, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550500 · Cited by 55
“Key players of lipid metabolism in TAMs, including PPAR g , PI 3-kinase, and the lipoxygenases, promote the formation of a tumor immunosuppressive microenvironment and facilitate immune escape (222 – 225).”
Nanotherapy of Glioblastoma—Where Hope Grows
Grzegorzewski, J., Michalak, M., Wołoszczuk, M., Bulicz, M., & Majchrzak‐Celińska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051814 · Cited by 53
“Rather than a simple M1 vs. M2 binary system, macrophage polarization exists as a spectrum of activation states, where these two subtypes represent the extreme ends [195].”
The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
Moeckel, C. M., Bakhl, K., Georgakopoulos‐Soares, I., & Zaravinos, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076710 · Cited by 54
“TAMs are categorized as M1 or M2; M1 macrophages exhibit anti-tumor responses, while M2 macrophages promote tumor growth through several mechanisms including neovascularization, angiogenesis, and modification of stromal cells for greater tumor support [22,23].”
BackgroundTang, W., Lo, C. W. S., Ma, W., Chu, A. T.-W., Tong, A. H. Y., & Chung, B. H. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01218-4 · Cited by 53
“TAMs play crucial roles in therapy resistance by promoting cancer cell survival, inducing angiogenesis and suppressing CD8 + T cell function through cell–cell interactions, suppressive cytokine secretion, and immune checkpoint upregulation [18–20].”
BackgroundWei, J., Dai, Y., Zhang, N., Wang, Z., Tian, X., Yan, T., Jin, X., & Jiang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1408377 · Cited by 58
“…usually expressing CD206 and CD163, are regulated by a variety of transcription factors and secreted cytokines in regulating tumor growth, thereby modulating in fl ammation, suppressing immune response, and stimulating cellular and tissue remodeling, angiogenesis and tumor progression (29, 30).”
BackgroundTumor-Associated Extracellular Matrix Obstacles for CAR-T Cell Therapy: Approaches to Overcoming
Klabukov, I., Kabakov, A. E., Yakimova, A. O., Baranovskii, D., Сосин, Д. В., Atiakshin, D., Ignatyuk, M. A., Yatsenko, E., Rybachuk, V. A., Evstratova, E. S., et al. (2025) · Current Oncology · doi:10.3390/curroncol32020079 · Cited by 55
“…may undergo pro-tumor M2 polarization and then contribute to tumor progression and metastasis by generating growth factors such as TGF β , VEGF, EGF, FGF, and PDGF; proinflammatory factors such as TNF α , IL1 β , IL6, and IL12; and immunosuppressive factors such as IL10 and PGE2 [39,40].”
Pakravan, K., Mohammadi, M. M., Ghazimoradi, M. H., Cho, W. C. S., Sadeghizadeh, M., & Babashah, S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03780-2 · Cited by 50
“The M1/M2 polarization of macrophages is endowed with a repertoire of tumor-promoting capabilities involving tumor growth and metastasis, tissue remodeling, and immunosuppression [6].”
BackgroundMechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Zhou, K., Li, S., Zhao, Y., & Cheng, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127071 · Cited by 56
“After that, TAMs undergo M2 polarization in response to signals in the TME (102).”
BackgroundCAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar
Chen, K., Liu, M., Wang, J., & Fang, S. (2024) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9675 · Cited by 49
“It is well established that TAMs, exhibiting M2 phenotypes, are prompted by certain cancer cells to construct a dense ECM around the tumor [52–54].”
BackgroundTherapeutic challenges in peripheral T-cell lymphoma
Luan, Y., Li, X., Luan, Y., Luo, J.-Y., Dong, Q., Ye, S., Li, Y., Li, Y., Jia, L., Yang, J. J. J., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01904-w · Cited by 60
“…described, GATA3 expression in PTCL-NOS is associated with a poor prognosis [39] and is characterized by type 2 helper t cell (Th2) -related cytokines, including interleukin (IL)-4, IL-5, IL-10, and IL-13 [48], which promote macrophage polarization to alternative M2-type macrophages [49].”
BackgroundZhang, W., Zhu, Y., Liu, H., Zhang, Y., Liu, H., Adegboro, A. A., Dang, R., Dai, L., Wanggou, S., & Li, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00570-5 · Cited by 53
“M1 macrophages are signi fi cant in their contribution to antitumor immunity and the inhibition of cancer progression, through activities such as tumor suppression, initiation of immune responses, tissue remodeling, antigen presentation, and promotion of in fl ammation 39 .”
Chen, W., Chen, M., Hong, L., Abudukeremu, X., Huang, M., Tang, N., Yang, X., She, F., & Chen, Y. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00550-2 · Cited by 52
Li, Y., You, J., Zou, Z., Sun, G., Shi, Y., Sun, Y., Xu, S., & Zhang, X. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.114222 · Cited by 54
Cancer-on-a-chip for precision cancer medicine
Liu, L., Wang, H., Chen, R., Song, Y., Wei, W., Baek, D. S. H., Gillin, M., Kurabayashi, K., & Chen, W. (2025) · Lab on a Chip · doi:10.1039/d4lc01043d · Cited by 52
Jin, G., Guo, N., Liu, Y., Zhang, L., Liang, C., Dong, T., Liu, W., Zhang, X., Jiang, Y., Lv, G., et al. (2023) · Theranostics · doi:10.7150/thno.83163 · Cited by 49
“CHIL3 (CHI3L1 in human) proteins are synthesized by various cell types and best known as a biomarker secreted by M2 macrophages in various diseases [22, 23].”
BackgroundMagnesium alloys in tumor treatment: Current research status, challenges and future prospects
Hsu, Y., Lu, Y., Wang, S., Zheng, Y., Xia, D., & Liu, Y. (2023) · Journal of Magnesium and Alloys · doi:10.1016/j.jma.2023.08.008 · Cited by 48
Yu, G., Corn, P. G., Mak, C. S. L., Liang, X., Zhang, M., Troncoso, P., Song, J. H., Lin, S.-C., Song, X., Liu, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402903121 · Cited by 54
“The polarization of TAMs is directly controlled by cytokines within the TME (36).”
BackgroundMacrophages in tumor cell migration and metastasis
Friedman, M., Karagiannis, G. S., Condeelis, J. S., Oktay, M. H., & Entenberg, D. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1494462 · Cited by 53
Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers
Kotsifaki, A., Alevizopoulos, N., Dimopoulou, V., & Armakolas, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015332 · Cited by 52
“This polarization can inhibit anti-tumor immune responses and promote immuno-suppression [86,87].”
BackgroundWu, J., Dong, W., Pan, Y., Wang, J., Wu, M., & Yu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296783 · Cited by 52
“M1 macrophages are induced by bacterial products and interferons related to type 1 immune responses, while M2 macrophages are induced by cytokines involved in type 2 immune responses such as IL-4 and IL-13 (39).”
BackgroundGuo, S., Li, Z., Zhou, R., Feng, J., Huang, L., Ren, B., Zhu, J., Huang, Y., Wu, G., Cai, H., et al. (2024) · Small · doi:10.1002/smll.202309842 · Cited by 48
Polyamines: the pivotal amines in influencing the tumor microenvironment
Holbert, C. E., Casero, R. A., & Stewart, T. M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01034-9 · Cited by 55
“The differentiation of macrophages is determined by the cytokines and growth factors present in the tissues in which they infiltrate [95, 96].”
BackgroundWang, Y., Wang, Q., Tao, S., Li, H., Zhang, X., Xia, Y., Wang, Y., Yang, C. Z., & Sui, C. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217199 · Cited by 54
Role of polyamines in intestinal mucosal barrier function
Nakamura, A., & Matsumoto, M. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-024-01035-4 · Cited by 46
“Within the tumor microenvironment, M2 macrophages, commonly deemed TAMs, are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis [129].”
Zhang, Y., Zhang, X., Meng, Y., Xu, X., & Zuo, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108994 · Cited by 54
Zhang, Y., Zhang, B., Lv, C., Zhang, N., Xing, K., Wang, Z., Lv, R., Yu, M., Xu, C., & Wang, Y. (2023) · Theranostics · doi:10.7150/thno.81407 · Cited by 50
“Meanwhile, hypoxia not only directly affects macrophage polarization, but can have indirect effects by altering the communication between tumor cells and macrophages [42, 48, 49].”
BackgroundDong, Y., Wang, G., Nie, D., Xu, Y., Bai, X., Chang-yong, L., Jian, F.-Y., Wang, H., & Zheng, X. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111217 · Cited by 47
The role of tumor-associated macrophages in oral squamous cell carcinoma
Xue, Y., Song, X. J., Fan, S., & Deng, R. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.959747 · Cited by 48
“At the early stage of tumor progression, TAMs mainly present the M1 phenotype, with anti-tumor properties (Boutilier and Elsawa, 2021).”
BackgroundWang, M., Zhang, L., Chang, W., & Zhang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096551 · Cited by 45
Luo, H., Ma, W., Chen, Q., Yáng, Z., & Dai, Y. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102042 · Cited by 44
Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer
Li, M., Ye, W., & Luo, K.-W. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070865 · Cited by 56
“Three main functions of these cells are phagocytosis, exogenous antigen presentation, and immunomodulation through the secretion of cytokines and growth factors [3].”
BackgroundWang, X., Yang, J., Yang, W., Sheng, H., Jia, B., Peng, C., Xu, S., Hong, X., Jiang, C., Yang, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.10.026 · Cited by 54
“Actually, this polarization is linked to an immunosuppressive microenvironment that supports tumor growth, invasion, and metastasis [155].”
Jafarzadeh, S., Nemati, M., Zandvakili, R., & Jafarzadeh, A. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114345 · Cited by 45
Interactions between cancer cells and tumor-associated macrophages in tumor microenvironment
Liu, L., Li, Y., & Li, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189344 · Cited by 51
Elomaa, H., Ahtiainen, M., Väyrynen, S. A., Ogino, S., Nowak, J. A., Lau, M. C., Helminen, O., Wirta, E., Seppälä, T. T., Böhm, J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02238-6 · Cited by 44
“Macrophages are inflammatory cells which have shown to associate with cancer progression [6].”
BackgroundPawar, J. S., Salam, M. A., Dipto, M. S. U., Al-Amin, M. Y., Salam, M. T., Sengupta, S., Kumari, S., Gujjari, L., & Yadagiri, G. (2025) · Cancers · doi:10.3390/cancers17152484 · Cited by 49
“On the contrary, M2-TAMs create an immunosuppressive TME and favor tumor cells for invasion, metastasis, angiogenesis, and remodeling of the ECM by secreting high levels of anti-inflammatory cytokines such as interleukin IL-4, IL-13, and IL-10 [83].”
Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies
Wang, X., He, J. N., Ding, G., Tang, Y., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688699 · Cited by 66
O-GlcNAcylation and Its Role in Cancer-Associated Inflammation
Ouyang, M., Yu, C., Deng, X., Zhang, Y., Zhang, X., & Duan, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861559 · Cited by 47
“Currently, Imiquimod (a TLR7 agonist) is now FDA-approved for topical administration in squamous and basal cell carcinoma (142).”
BackgroundAnnexin A5 as a targeting agent for cancer treatment
Woodward, A., Faria, G. N. F., & Harrison, R. G. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215857 · Cited by 45
Zhao, F., He, Y., Zhao, Z., He, J., Huang, H., Ai, K., Liu, L., & Cai, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272133 · Cited by 42
“Macrophages are essential components of innate immunity and exhibit signi fi cant heterogeneity and polarization (40).”
BackgroundNanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy
Xiao, Z., Tan, Y., Cai, Y., Huang, J., Wang, X., Li, B., Lin, L., Wang, Y., Shuai, X., & Zhu, K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.029 · Cited by 46
Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment
Carreira, L. D., Oliveira, R. I., Moreira, V. M., & Salvador, J. A. R. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2266571 · Cited by 42
“Whereas M1 macrophages are abundant at early stages of cancer suppressing tumor cell growth, M2 macrophages appear when the tumor environment is established and are involved in metastasis, angiogenesis and proliferation of malignant cells [93].”
BackgroundIntratumoral microbiota: implications for cancer onset, progression, and therapy
Wu, J., Zhang, P., Mei, W., & Zeng, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1301506 · Cited by 46
“…the Th1 subtype and CD8 + T cells with cytotoxic activity, accompanied by a shift towards Th2 T cells, as well as the shift of tumor-associated macrophages (TAMs) towards the M2 phenotype associated with immunosuppression, are associated with immune suppression and an unfavorable TME (78, 81, 82).”
BackgroundXu, D., Wang, W., Wang, D., Ding, J., Zhou, Y., & Zhang, W. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.01.015 · Cited by 46
“TAMs are an essential part of the TME, and based on their polarization state, they may have pro-or anti-tumorigenic effects [205,206].”
BackgroundFeng, Y., An, Q., Zhao, Z., Wu, M., Yang, C., Liang, W., Xu, X., Jiang, T., & Zhang, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116266 · Cited by 43
Wang, L., Wang, W., Hu, D., Liang, Y., Liu, Z., Zhong, T., & Wang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1346587 · Cited by 45
“Macrophages exhibit different phenotypes that are broadly classi fi ed into two types: classically activated M1-like macrophages and alternatively activated M2-like macrophages, depending on the TME (31, 32).”
Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements
Adewuyi, E. E., Chorya, H. P., Muili, A. O., Moradeyo, A. A., Kayode, A. T., Naik, A., Odedele, J. T., & Obasanjo, O. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104575 · Cited by 49
Yi, B., Dai, K., Yan, Z., & Yin, Z. (2022) · Bioengineered · doi:10.1080/21655979.2021.2003929 · Cited by 43
Zheng, X., Li, X., Meng, S., Shi, G., Li, H., Du, H., Dai, L., & Yang, H. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01878-3 · Cited by 41
“In general, TNF-α and IL-6 are considered to be the special markers of M1 macrophages, and IL-10 is considered to be the special marker of M2 macrophages [27].”
Du, A., Yang, Q., Sun, X., & Zhao, Q. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110868 · Cited by 48
Li, C., Liu, C., Zhang, J., Lu, Y., Jiang, B., Xiong, H., & Li, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296687 · Cited by 42
Lu, X., Luo, Y., Nie, X., Zhang, B., Wang, X., Li, R., Liu, G., Zhou, Q., Liu, Z., Fan, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44305-9 · Cited by 47
“M1 macrophages are considered to have anti-tumor properties, whereas M2 macrophages historically exhibit pro-tumorigenic functions 69,70 .”
Pan, J., Zhang, J., Lin, J., Cai, Y., & Zhao, Z. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1343140 · Cited by 43
“M2-polarized macrophages are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis (Boutilier and Elsawa, 2021).”
The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma
Lu, Y., Lin, B., & Li, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1363695 · Cited by 47
“A signi fi cant number of macrophages in fi ltrate the tumor stroma, referred to as tumor-associated macrophages (TAMs) (45).”
BackgroundShebbo, S., Alateyah, N., Yassin, E., Mahmoud, D. E. S., Tamimi, F., Anweigi, L. M., Elhissi, A. M. A., Abou-Saleh, H., Elrayess, M. A., & Agouni, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1626243 · Cited by 44
Mishra, V., Tripathi, V., Yadav, P., & Singh, M. P. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123617 · Cited by 46
Dominguez-Cejudo, M. A., Gil-Torralvo, A., Solís, M. C., Molina‐Pinelo, S., & Bofill, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316771 · Cited by 45
“M1 refers to macrophages that undergo classical activation via interferon-γ (IFN γ ) with either lipopolysaccharide (LPS) or TNF, whereas M2 refers to macrophages that undergo alternative activation via IL-4 [26].”
BackgroundChen, J., Tang, Y., Qin, D., Yu, X., Tong, H., Tang, C., & Tang, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04804-1 · Cited by 42
“It is generally believed that TAMs are more inclined to M2 phenotype [17, 18].”
BackgroundNew insights into the role of macrophages in cancer immunotherapy
Li, Z., Zhao, T., Zhang, R., Chen, C., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1381225 · Cited by 51
“M1 macrophages could produce multiple cytotoxic substances, such as nitric oxide and reactive oxygen species, and thereby activate the function of multiple immune cells and reduce microbial activity, ultimately eliminating microbial infection (14).”
BackgroundInfluentialBudi, H. S., & Farhood, B. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116432 · Cited by 41
Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers
Chupradit, K., Muneekaew, S., & Wattanapanitch, M. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03759-6 · Cited by 44
“As tumors progress, the M2-like population increases, promoting tumor growth, invasion, and metastasis [52, 53].”
BackgroundFiring up “cold” tumors: Ferroptosis causes immune activation by improving T cell infiltration
Li, X., Li, Y., Tuerxun, H., Zhao, Y., Liu, X., & Zhao, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117298 · Cited by 43
Mitophagy’s impacts on cancer and neurodegenerative diseases: implications for future therapies
Huang, J. B., Pham, V. T., Fu, S., Huang, G., Liu, Y., & Zheng, L. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01727-w · Cited by 45
“Given that cancer cells can control macrophage recruitment and polarization within TME, shifting macrophages from an M1 phenotype with anti-tumor properties to an M2-polarized macrophage (also known as TAM) promotes tumorigenesis [261].”
Identification of a six-gene prognostic signature for bladder cancer associated macrophage
Jiang, Y., Qu, X., Zhang, M., Zhang, L., Yang, T., Ma, M., Jing, M., Zhang, N., Song, R., Zhang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.930352 · Cited by 39
“From the above results, we can conclude that TAMs, especially M2 macrophages, may play an indispensable role in tumor progression. frontiersin.org Identification of TAM-related gene modules using WGCNA First, 430 patients were clustered using the R software (Supplementary Figure 1).”
BackgroundInfluentialExploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
Li, X.-M., Zhao, Z., Xiao, Y., Xia, Q., Zhou, P., Wang, S., Wu, H., & Hu, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00394-2 · Cited by 41
“When the stimulus in tissue microenvironment changes, the polarization state of macrophages will also be altered due to cellular plasticity [142, 143].”
BackgroundWu, J., Wang, X., Chen, L., Wang, J., Zhang, J., Tang, J., Ji, Y., Song, J., Wang, L., Zhao, Y., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.05.022 · Cited by 48
“These results were consistent of the findings of previous studies [24,39].”
ResultImmunotherapeutic strategies in head and neck cancer: challenges and opportunities
Liu, X., Harbison, R. A., Varvares, M. A., Puram, S. V., & Peng, G. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188128 · Cited by 45
“TME induces the polarization of macrophages and TAMs predominantly exhibiting an M1 phenotype at early tumor stages, when antigen presentation drives anti-tumor CD8 + T cell and NK cell recruitment (132).”
Metabolic Reprogramming in Tumor-Associated Macrophages in the Ovarian Tumor Microenvironment
Kumar, S., Mittal, S., Gupta, P., Singh, M., Chaluvally–Raghavan, P., & Pradeep, S. (2022) · Cancers · doi:10.3390/cancers14215224 · Cited by 42
“Recent research has shown that a system such as this is practical and perhaps helpful [78,79].”
BackgroundDNA Nanoclusters Combined with One‐Shot Radiotherapy Augment Cancer Immunotherapy Efficiency
Xie, Y., Li, H., Xu, L., Zou, H., Wang, X., He, X., Tang, Q., Zhou, Y., Zhao, X., Chen, X., et al. (2023) · Advanced Materials · doi:10.1002/adma.202208546 · Cited by 40
Epigenetic regulation and therapeutic targets in the tumor microenvironment
Xie, Z., Zhou, Z., Yang, S., Zhang, S., & Shao, B. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00126-2 · Cited by 42
Wnt Signaling in the Phenotype and Function of Tumor-Associated Macrophages
Tigue, M. L., Loberg, M. A., Goettel, J. A., Weiss, W. A., Lee, E. N., & Weiss, V. L. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1403 · Cited by 42
Angiogenesis Still Plays a Crucial Role in Human Melanoma Progression
Cazzato, G., Ingravallo, G., & Ribatti, D. (2024) · Cancers · doi:10.3390/cancers16101794 · Cited by 37
“While alternatively activated myeloid cells are anti-inflammatory and promote tumor growth, classically activated neutrophils, macrophages, and MDSCs exhibit pro-inflammatory and anti-tumor properties [110–122].”
BackgroundMacrophage polarization in sepsis: Emerging role and clinical application prospect
Hou, F., Mi, J. H., Wang, Q., Tao, Y. L., bin Guo, S., Ran, G. H., & Wang, J. C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113715 · Cited by 40
Macrophage polarization regulates the pathogenesis and progression of autoimmune diseases
Wu, S., Zhao, S., Hai, L., Yang, Z., Wang, S., Cui, D., & Xie, J. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103820 · Cited by 38
Reprogramming the tumor microenvironment with biotechnology
Kim, M., Lee, N. K., Wang, C. J., Lim, J., Byun, M. J., Kim, T. P., Park, W., Park, D.-H., Kim, S.-N., & Park, C. G. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00343-4 · Cited by 43
“However, in the TME, M1 is an anti-tumor phenotype and M2 is a pro-tumor phenotype [33].”
BackgroundWang, B., Cheng, D., Ma, D., Chen, R., Li, D., Zhao, W., Fang, C., & Ji, M. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01473-5 · Cited by 41
“They can be roughly categorized into anti-tumor M1 type and pro-tumor M2 type, although TAMs predominantly exhibit an M2 phenotype [10].”
BackgroundZhen, M., Xu, Y. M., Wang, C., & Bai, C. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202409319 · Cited by 37
Xiong, K., Sun, W., He, Y., & Fan, L. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-465 · Cited by 35
“In addition, M2 TAMs express TGF-β, EGF, the molecules play roles in inhibiting apoptosis and prompting tumor cells proliferation to affect tumor progress directly (68).”
Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
Batra, H. V., Mouabbi, J. A., Ding, Q., Şahin, A. A., & Raso, M. G. (2023) · Cancers · doi:10.3390/cancers15225491 · Cited by 43
“Macrophages in the TME are broadly classified as M1 and M2 based on their antitumori-genic and protumorigenic potential [150].”
BackgroundLiu, K., Wang, H., Zhou, J., Zhu, S., Ma, M., Xiao, H., & Ding, Y. (2023) · Cell Biology International · doi:10.1002/cbin.12110 · Cited by 37
“TAMs infiltrate cancer tissues and polarize into classically activated M1 ‐ like pro ‐ inflammatory macrophages or M2 ‐ like immunosuppressive macrophages (Boutilier & Elsawa, 2021; Pan et al., 2020).”
Background
Metadata
- Authors
- Boutilier, A. J., & Elsawa, S. F.
- Affiliations
- University of New Hampshire (US)
- Corresponding author
- Elsawa, Sherine F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-29
- Volume
- 22
- Issue
- 13
- Pages
- 6995
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8268869
- OpenAlex
- W3173665490
- Cited by
- 1,631
- References
- 148
- Citations by year
- 2026: 281 · 2025: 409 · 2024: 429 · 2023: 359 · 2022: 144 · 2021: 9
- FWCI
- 24.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (P20 GM113131)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- macrophage polarization, tumor-associated macrophages, tumor microenvironment, tumor progression, angiogenesis, lymphangiogenesis, immunosuppression, hypoxia, metastasis, macrophage recruitment
- MeSH terms
- Tumor-Associated Macrophages, Animals, Hypoxia, Cell Transformation, Neoplastic, Humans, Inflammation, Macrophage Activation, Neoplasm Metastasis, Neoplasm Staging, Signal Transduction, Biomarkers, Immunophenotyping, Cytokines, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.